Jinan Jiage biological technology co., LTD(expird)
Free supplier
- Free
supplier - 8th
years
Free supplier
Business Type:Trading Company
Product Certification&
Enterprise Certification
Country: 
China (Mainland)
Business Type:Trading Company
CAS NO.139110-80-8
Enterprise Standard(1-10)GramEnterprise Standard(11-100)Gram
High quality pharma grade 99% Zanamivir hydrate for Anti-viral
| CAS | 139110-80-8 |
| MF | C12H20N4O7 |
| MW | 332.31 |
| Purity | 99% |
|
Appearance |
White to off-white powder |
| Certification |
HSE, ISO 9001, USP, BP
|
| Standard | Enterprise Standard |
| Usage |
(1).Influenza viral neuraminidase inhibitor; structural analog of the sialic acid. Antiviral (2).antineoplastic, anti-metabolite |
| Packing | Discreet packing ways as your requirement, 100% go through |
| Storage | Discreet packing ways as your requirement, 100% go through |
Zanamivir Hydrate--------------Description:
Zanamivir is a sialic acid-analogue neuraminidase inhibitor with antiviral activity. Administered into the respiratory tract by aerosol inhalation, zanamivir selectively binds to and inhibits influenza A and B virus neuraminidase-mediated cleavage of sialic acid residues in host cell membrane-bound glycoprotein receptors for influenza viruses, preventing the release of progeny viruses from host cell surfaces and, so, further viral replication.
Zanamivir Hydrate---------------Therapeutic Uses:
Zanamivir is indicated for the treatment of uncomplicated acute illness due to influenza A virus in adults and children 7 years and older who have been symptomatic for no more than 2 days. Zanamivir must be started within 48 hours after the onset of influenza symptoms.
Zanamivir is indicated for the treatment of uncomplicated acute illness due to influenza B virus in adults and children 7 years and older who have been symptomatic for not more than 2 days. Zanamivir must be started with 48 hours after the onset of influenza symptoms.
Zanamivir is indicated for the prophylaxis of influenza A and B. Although not a substitute for use of zanamivir may be considered if the vaccine is not available, in conjunction with the vaccine late in the influenza season, before the vaccine has induced an immune response, or if there is not immune response to the vaccine.